|Day Low/High||300.52 / 316.65|
|52 Wk Low/High||295.27 / 442.00|
An inverse head and shoulders pattern could soon develop.
These four names are soaring, and I'd jump into all of them, even after their recent runs.
Auto-loan regulation could rattle some publicly traded auto dealers.
Skittish buyers are only nibbling and leaving plenty of good cheap stocks for you.
Apparently it's 'bad' now that the public has stopped pulling reams of money out of the market.
Treasuries are calling the tune today, regardless of companies' fundamentals.
Though data suggest a softer eurozone recovery than expected, EverBank's Frank Trotter says it's unlikely the ECB will cut rates.
Merck is shunned by all; Biogen is liked by all; and Bristol-Myers is the holy grail.
We're getting positive news from businesses all over the place -- yet none of it will matter if the U.S. defaults.
Jim Cramer reflects on 2,000 episodes for Mad Money and the importance of individual stock picking.
These stocks look bound to get bought at every dip through year-end. You should buy up, too -- but wait for that swoon.
Dan Fitzpatrick, founder of StockMarketMentor.com, details three stocks Jim Cramer discussed on CNBC's "Mad Money" and how to trade them.
There have been some really good winners this year. By Bob Lang One of the best sectors to play this year has been the biotechs and I would be remiss if I didn't tell you my best play ever was just a couple weeks ago with Onyx Pharmaceutical (ONXX),...